Understanding how AOD 9604 targets fat reveals a mechanism that separates lipolysis from IGF-1 stimulation entirely. Here is the C-terminus science that makes it a clean research tool for fat metabolism.
Understanding how AOD 9604 targets fat is the key to appreciating why this compound has attracted serious research attention as a metabolic tool. Most lipolytic research compounds that interact with the growth hormone axis produce a bundle of effects — fat mobilization, IGF-1 elevation, insulin resistance, and anabolic signaling — that make it difficult to study fat metabolism in isolation. AOD-9604 separates the fat-targeting mechanism from that bundle entirely, giving researchers a cleaner tool for studying adipose tissue metabolism specifically.
The reason it can do this comes down to which part of the growth hormone molecule it replicates.
Human growth hormone (hGH) is a 191-amino acid peptide with multiple functional domains. The N-terminal region of the molecule handles the anabolic and metabolic growth functions — including IGF-1 stimulation and the insulin-antagonist effects that characterize supraphysiological GH exposure. The C-terminal region, specifically amino acids 177-191, is responsible for the lipolytic (fat-burning) activity.
AOD-9604 is a synthetic peptide comprising that C-terminal fragment — amino acids 177-191 — with a tyrosine added at the N-terminus for stability. By isolating this fragment, researchers can study fat oxidation and lipolysis without the IGF-1 elevation, cartilage growth, or insulin resistance that full-length GH or GH secretagogues produce. This is not a minor distinction in research design — it means that fat metabolism can be studied as an isolated variable rather than as one output of a complex multi-pathway GH signal.
The original AOD-9604 lipolysis research in Obesity Research demonstrated that the C-terminal fragment retained the lipolytic activity of full-length GH in obese rodent models while producing no measurable effect on IGF-1 levels or linear growth — confirming that the fat-targeting mechanism is functionally separable from the anabolic mechanism at the molecular level.
AOD-9604 acts on fat tissue through two complementary mechanisms: it stimulates lipolysis (the breakdown and release of stored triglycerides from adipocytes) and simultaneously inhibits lipogenesis (the synthesis of new fat from carbohydrate and other precursors). This dual action means it is not simply accelerating fat release — it is also reducing the rate at which new fat is being stored, producing a net shift in adipose tissue mass over time in research models.
The lipolytic mechanism involves the beta-3 adrenergic receptor — a receptor expressed preferentially on adipocytes, particularly in subcutaneous fat depots. AOD-9604 activation of this receptor triggers the cAMP-PKA cascade inside the fat cell, which activates hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) — the two primary enzymes responsible for breaking down stored triglycerides into free fatty acids and glycerol for release into circulation.
The lipogenesis inhibition occurs through a separate pathway involving suppression of fatty acid synthase (FAS) activity. FAS is the enzyme complex responsible for synthesizing new fatty acids from acetyl-CoA, and its suppression reduces the rate of de novo lipogenesis in adipose tissue. In animal model research, this dual mechanism produces greater reductions in fat mass than lipolysis stimulation alone would predict — the compound is both releasing stored fat and preventing its replacement.
The absence of insulin antagonism is one of the most practically significant properties of AOD-9604 for metabolic research design. Full-length GH stimulates lipolysis but does so in a way that generates free fatty acids that compete with glucose for oxidation in peripheral tissues — a well-documented mechanism of GH-induced insulin resistance. This complicates research design whenever glycemic control is an endpoint or confounding variable.
AOD-9604's C-terminal fragment lacks the structural domain that mediates GH's insulin-antagonist effects. The free fatty acids released by AOD-9604-stimulated lipolysis enter circulation and are oxidized by muscle and liver tissue without producing the insulin resistance phenotype associated with full-length GH. In rodent research, fasting glucose and insulin sensitivity markers have remained stable during AOD-9604 administration at doses producing significant lipolytic effects — a combination that does not occur with GH itself.
Join 10,000+ researchers. Get your discount code, early access to new compounds, and protocol insights.
No spam, ever. Unsubscribe anytime.
Check your inbox for your discount code.
Here's a preview:
Valid on all products · Single use
